SY-5609-101 (Syros)
Description: A Phase 1 Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients with Select Advanced Solid Tumors
Mechanism of Action: CDK7 inhibitor
Target Patient Population: Metastatic breast cancer, ovarian, lung, colorectal or any malignancy with mutation of RB1, CDKN1A/CDKN2A, amplification of CCNE1, CCND1, CCND2, CDK4 or CDK6); in combination with gemcitabine or gemcitabine/nab-paclitaxel in pancreatic cancer
Study Design: Drug is given orally daily.